Vista Pharmaceuticals Ltd — Updates, 21-04-2025: Company Update

Vista Pharmaceuticals has announced a board meeting to discuss compliance with SEBI regulations, specifically regarding the dematerialization of securities for the quarter ended March 31, 2025. The company confirms that securities received for dematerialization were correctly processed, mutilated, and cancelled, with the depository's name updated in their records.

This compliance indicates the company's commitment to maintaining proper governance and operational transparency, which may enhance shareholder confidence. The smooth execution of dematerialization procedures could reflect positively on the company’s operational efficiency, contributing to a stable investor sentiment.